Scientific Advisory Board

HOME > Our Network > Scientific Advisory Board

KDDF have utilized whole Korean R&D community for project evalutaion.

  • The project embraces the full lifecycle of novel drug development from the discovery to clinical stage.
  • The member of evaluation committee have been updated regularly in order to maintain professional assessments.
  • Currently, evaluation committee for KDDF consists of 693 members. The committee embraces balanced diversity by selecting members with various fields of professional experience. These fields include: academia (58.6%), industry (30.2%), public organizations and supported research institutes (6.9%) and others (4.3%).

 

Clinical Advisor

  • Clinical trial specialists for each disease area, providing a consulting service.

 

Licensing Advisor

  • Advisory board which consists of approximately 7 executive-level advisors from global pharmaceutical companies.
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code